Editorial
|
|
|
|
|
France's Health Authority must withdraw risky guidelines
|
|
|
|
Marketing Authorisations
|
|
|
|
|
No better than methylphenidate
|
|
|
|
|
|
|
|
|
|
Adding laropiprant adds adverse effects
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Romiplostim is a better option
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
News update: benfluorex withdrawn from the French market
|
|
|
|
|
|
|
|
|
|
Often predictable and preventable
|
|
|
|
|
|
|
|
|
|
Pharmacovigilance databases
|
|
|
|
|
|
|
|
|
|
|
|
Preventing overdose with fentanyl transdermal patches
|
|
|
|
|
|
|
|
|
|
|
|
Caution in some circumstances
|
|
|
|
|
|
|
|
|
|
Lowest effective doses should be determined
|
|
|
|
|
|
|
|
|
|
Teach parents to use the INN, not the brand name
|
|
|
|
|
|
|
|
|
|
|
|
Propylthiouracil a safer option during pregnancy
|
|
|
|
Reviews
|
|
|
|
|
Methotrexate first
|
|
|
|
|
|
|
|
|
|
Control glycaemia and blood pressure, and monitor the eyes
|
|
|
|
|
|
|
|
|
|
Liver biopsy is not always necessary
|
|
|
|
Outlook
|
|
|
|
|
Credibility is at stake
|
|
|
|
|
|
|
|
|
|
Taking clinical data, pharmacology and patient characteristics into account
|
|
|
|
|
|
|
|
|
|